Brain [52FE]-Transferrin Uptake in Patients with Alzheimer’s Disease and Healthy Subjects: A Positron Emission Tomography (PET) Study
Alteration of cerebral iron metabolism is involved in several neurodegenerative disorders like Parkinson’s disease and Alzheimer’s disease. However, it is still difficult to understand whether changes in cerebral iron levels are primarily related to the pathological process or secondary to the disease state. Transferrin (Tf) is the major iron carrier protein in plasma. The transport of iron into brain involves the binding of the iron-Tf complexes to high affinity Tf receptors (TfR) which are located in the brain capillary membranes of the blood brain barrier (BBB). The complex Tf-TfR is then internalized into cells where the iron is released. Other metals like aluminium or manganese also bind to transferrin and may be transported into brain in a similar manner as iron. Neuropathological studies using [125I]-transferrin have shown increased binding in cerebral microvessels in AD patients compared to age matched healthy controls . We have shown previously that blood to brain iron uptake can be measured using the tracer [52Fe]-citrate and positron emission tomography (PET) [2–3]. [52Fe] is a positron emitter which rapidly and almost completely binds to plasma Tf after intravenous injection.
KeywordsPositron Emission Tomography Brain Iron Neurofibrillary Degeneration Cerebral Microvessels Citrate Uptake
Unable to display preview. Download preview PDF.
- 2.Leenders KL, Antonini A, Schwarzbach R, Smith-Jones P, Reist H, Ben-Sachar D, Youdim M, Henn V. Blood to brain iron in one monkey using [52Fe]-citrate and positron emission tomography (PET). J Neuronal Transm 1994; 43: 123–132.Google Scholar
- 3.Leenders KL, Antonini A, Schwarzbach R, Smith-Jones P, Pellika R, Günther I, Psylla M, Reist H. Blood to brain iron transport in man using [52Fe]-citrate and positron emission tomography (PET). In: Uemura K (ed) Quantification of brain function. Tracer kinetics and image analysis in brain PET. Elsevier, Amsterdam 1993 145-150Google Scholar
- 4.McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Service Task Force on Alzheimer’s Disease. Neurology 1984; 34:939–944.PubMedCrossRefGoogle Scholar
- 5.Smith-Jones P, Schwarzbach R, Weinreich R The production of 52Fe by means of a medium energy proton accelerator. Radiochem Acta 1990; 50: 33–39.Google Scholar
- 13.McLachlan DRC, Dalton AJ, Kruck TPA, Bell MY, Smith WL, Kalow W, Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991; 337:1304-1308.Google Scholar